# Open Label Extension for GLYX13-C-202, NCT01684163

> **NCT02192099** · PHASE2 · TERMINATED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 61 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Rapastinel (225 mg/450 mg IV administration)

## Key facts

- **NCT ID:** NCT02192099
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-08
- **Primary completion:** 2018-11-08
- **Final completion:** 2018-11-08
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Patients from this study were rolled into RAP-MD-99.
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02192099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02192099, "Open Label Extension for GLYX13-C-202, NCT01684163". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02192099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*